Pancreatic cancer is a frequent cause of cancer-related mortality and has an extremely poor prognosis. To evaluate the efficacy of allogeneic hematopoietic SCT with reduced-intensity conditioning (RICT) against pancreatic cancer, we analyzed the clinical data of 22 patients. After a fludarabine-based conditioning regimen followed by the infusion of PBSCs, all but two achieved engraftment. Complete, partial and minor response was observed in 1, 2 and 2 patients, respectively, with an overall response rate of 23%. Median survival was only 139 days and the major cause of death was tumor progression. Poor performance status before RICT and a lower number of infused CD34-positive cells were associated with shorter survival after RICT. Patients who developed chronic GVHD tended to survive longer than those who did not. These findings support the investigation of a novel treatment strategy to enhance the immunological effect against pancreatic cancer.
Introduction
Allogeneic hematopoietic SCT is an established treatment for a variety of hematological disorders. However, its application has been limited to young patients because of various complications including regimen-related toxicities, GVHD, infection and so on. Therefore, SCT with reducedintensity conditioning (RICT) has been investigated for use in older or clinically infirm patients. The antitumor effect of this therapeutic approach depends not only on the antineoplastic agents and/or irradiation in the conditioning regimen, but also on the immunological graft-versus-tumor effect after RICT. 1 Although RICT has not been clearly shown to have a clinical advantage over conventional chemotherapy, some studies have suggested that RICT may be beneficial in elderly patients with hematological malignancies. 2 Since the late 1990s, several studies of RICT against advanced solid tumors have been performed to harness the graft-versus-tumor effect. 3 A clinical tumor response after RICT was observed in several solid tumors, especially in renal cell cancer and breast cancer. [4] [5] [6] Pancreatic cancer is the fifth most common cause of cancer-related mortality in Japan and the United States, and carries an extremely poor prognosis. The median duration of survival in advanced pancreatic cancer is less than 6 months, even when patients are treated with gemcitabine. 7 The combination of gemcitabine with the other chemotherapeutic agents failed to significantly improve survival. [8] [9] [10] Furthermore, although the combination of gemcitabine and erlotinib, a molecular targeting agent against epidermal growth factor receptor, significantly prolonged survival, the difference in median survival was only 2 weeks. 11 Because of this poor prognosis by chemotherapy, treatment strategies to enhance immunological effects against pancreatic cancer have been investigated. One of these is a vaccination targeting tumor-specific antigens such as CA19-9 and CEA. 12 Another strategy is RICT to harness a strong allogeneic immunological antitumor effect. The first successful application of RICT against pancreatic cancer was reported in 2001. 13 Several other reports have suggested the existence of an immunological graftversus-tumor effect against pancreatic cancer, but the number of patients in each report was too small to draw any meaningful conclusion.
14,15 Therefore, we collected the clinical results of RICT against pancreatic cancer from transplantation centers in Japan, in which a prospective clinical trial of RICT against pancreatic cancer had been performed.
Patients and methods
We surveyed transplantation centers in Japan and identified three centers (Komagome Hospital, Kyushu University and National Cancer Center Hospital) that were performing a prospective clinical trial against various advanced solid tumors including pancreatic cancer. The University of Tokyo Hospital was performing a trial that exclusively included patients with advanced pancreatic cancer. Two of these trials have already been published. 14, 15 We collected the clinical results of all patients with pancreatic cancer who participated in these studies from the published papers or using a questionnaire.
The reduced-intensity conditioning regimens were exclusively fludarabine-based, but varied among centers. The most intensive regimen was the combination of fludarabine (30 mg/m 2 /day for 6 days), BU (4 mg/kg/day for 2 days) and gemcitabine (1000 mg/m 2 /day for 3 days) at the University of Tokyo Hospital, whereas the combination of fludarabine (30 mg/m 2 /day for 3 days) and TBI at 2 Gy (Kyushu University) was the least intensive. CY (60 mg/kg/ day for 2 days) was combined with fludarabine (25 mg/m 2 / day for 5 days) in the Komagome Hospital. Prophylaxis against GVHD was performed with CYA either alone or in combination with MTX or mycophenolate mofetil. PBSCs were mobilized with G-CSF, cryopreserved using standard techniques without ex vivo manipulation, thawed and infused on day 0. Host/donor T-cell chimerism was analyzed by sex-chromosome FISH or the short tandem repeat method after transplantation. 16 The tumor response to treatment was evaluated as described previously. 15 Briefly, CR (complete response) was defined as disappearance of all clinical evidence of tumor for a minimum of 4 weeks by computed tomography scan. MR (minor response) and PR (partial response) were defined as decreases of 25-50% and greater than 50%, respectively, in the sum of the products of the maximum diameter and its perpendicular diameter of all measurable lesions for a minimum of 4 weeks. 7 Engraftment was defined as a neutrophil count more than 500/mm 3 for 3 consecutive days after RICT. Engraftment failure was diagnosed as when engraftment was not achieved at any time after transplantation. The probability of survival was calculated using the Kaplan-Meier method. The incidence of chronic GVHD was evaluated in 13 patients who survived longer than 100 days after RICT. Univariate comparisons for dichotomous and time-to-event variables between groups were performed with the Fisher exact test and the log-rank test, respectively, and multivariate analyses were performed using logistic regression analysis and proportional hazards modeling, respectively. Factors associated with at least borderline significance (Po0.10) in the univariate analysis were subjected to a multivariate analysis using backward stepwise selection of covariates. All P-values were two sided and values of 0.05 or less were considered statistically significant.
Results
Clinical data of 22 patients with a median age of 57 years (range: 36-68 years) were collected (Table 1 ). There were 15 male and seven female patients. Fifteen patients had metastatic disease, whereas 7 had locally advanced diseases. All but one patient had received chemotherapy with gemcitabine either alone or in combination with other antineoplastic agents before RICT. In all, 10 had received local irradiation in addition to chemotherapy. Eastern Cooperative Oncology Group performance status (ECOG-PS) was equal to or greater than 2 in 10 patients. The conditioning regimen was fludarabine-BU-based in 10, fludarabine-CY in 7 and fludarabine-TBI in 5. The donors were HLA-matched relatives except in one patient who received graft from an HLA-mismatched family donor. The number of CD34-positive cells infused was greater than 4.0 Â 10 6 cells/recipient body weight (kg) in 10 patients. CYA was used for GVHD prophylaxis: alone in 8, combined with MTX in 10 and combined with mycophenolate mofetil in 4.
Engraftment was observed in all but two patients with a median duration from RICT of 12 days (range: 6-42 days). Complete donor-type T-cell chimerism was confirmed in 18 patients, whereas mixed chimerism persisted in 4 patients. A total of 12 patients developed grade II-IV acute GVHD. Limited and extensive chronic GVHD was observed in three and five patients, respectively, among the 13 patients who survived longer than 100 days after RICT.
The best response after RICT was CR in one, PR in two, MR in two and stable disease in eight. The overall response rate (CR þ PR þ MR) was 23%. A univariate analysis to identify possible relationships between clinical parameters and overall response failed to show any statistically significant factors. The conditioning regimen did not significantly affect the response rate, although the statistical power was not enough due to the small number of patients in each group. Response was observed in two of the seven patients who received the most intensive regimen including fludarabine, BU and gemcitabine, while it was seen in one of the six patients who received the least intensive regimen with fludarabine and low-dose TBI. None of the patients with mixed chimerism showed a response, but this difference was not statistically significant. DLI (donor lymphocyte infusion) was performed in four patients who had progressive disease after RICT, and the number of infused CD3-positive cells was between 2.7 Â 10 7 and 1.8 Â 10 8 cells/kg. One patient showed tumor shrinkage after DLI, but the response was transient. Figure 1a shows overall survival after RICT. Median survival was only 139 days and the major cause of death was tumor progression. Other causes of death included infection in one and chronic GVHD in two. In a univariate analysis, ECOG-PS below 2 and infused CD34-positive cell dose greater than 4.0 Â 10 6 cells/kg were associated with significantly longer survival after RICT (Table 2 ; Figures  1b and c) . A multivariate analysis revealed that these two factors were almost independently significant (Table 2) . With regard to post transplantation factors, while the development of grade II-IV acute GVHD did not significantly affect survival (P ¼ 0.76), the eight patients who developed chronic GVHD tended to survive longer than those who survived longer than 100 days after RICT but did not develop chronic GVHD (P ¼ 0.092; Figure 2 ). This analysis was unlikely to be biased by the fact that patients who survived longer had more chance to develop chronic GVHD, as most of the patients developed chronic GVHD as a progressive type from acute GVHD.
Discussion
To summarize these findings, 23% of the 22 patients in this series showed a response to RICT. However, the duration of the response was generally short and most of the patients eventually died with progressive disease. The median survival after RICT was only 139 days and only one survived longer than 1 year after transplantation. Good ECOG-PS and higher number of CD34-positive cells in the graft were independently associated with longer survival.
The relationship between the number of infused CD34-positive cells and transplant outcome has been studied in PBSC transplantation for hematological malignancies. 17 The infusion of a higher number of CD34-positive cells has been associated with faster recovery of neutrophils and plts, but chronic GVHD was more frequently observed in patients who received a very high dose of CD34-positive cells (that is, 48.0 Â 10 6 cells/kg). In this study, two patients failed to achieve engraftment, and both had received less than 4.0 Â 10 6 cells/kg of CD34-positive cells. However, a statistically significant survival advantage was confirmed even after these two patients were excluded from the analysis. If we consider that the major cause of death in this study was progressive disease, the infusion of a higher number of CD34-positive cells might have protected patients from disease progression by a graft-versus-host reaction, although we failed to show a significant difference between the number of infused CD34-positive cells and tumor response or the incidence of chronic GVHD, probably due to the small number of patients. Patients who developed chronic GVHD showed better survival than those who did not, with a borderline significance, suggesting that they had some immunological protection against the progression of pancreatic cancer. This study was limited by the heterogeneity of transplantation procedures among centers. However, considering the difficulty of performing a large-scale prospective study on RICT against pancreatic cancer, this small survey may currently represent the best evidence of the efficacy of this novel treatment strategy against advanced pancreatic cancer and may suggest a future direction for improving the treatment outcome. We showed that pancreatic cancer can be a possible target for allogeneic immunotherapy. However, the immunological effect was not strong or durable enough to prevent tumor progression. A possible strategy for enhancing a graft-versus-tumor effect against pancreatic cancer without enhancing GVHD is a combination with specific immunotherapy using antigens including CA19-9, CA242, CEA, Her-2, mutated K-ras and MUC-1.
12 Among these, CEA is attractive, since it is expressed in 85-90% of pancreatic cancer, and a specific immunotherapy against CEA could also be applied to other gastrointestinal cancers. An increase in the serum anti-CEA antibody level associated with a tumor response was observed in the University of Tokyo Study. 15 In addition, Kim et al.
18
showed that a peptide CEA652, TYACFVSNL, binds to HLA-A24 and induces CEA-specific cytotoxic T cells. Therefore, vaccination with such a peptide may be promising as a post transplantation immunotherapy against pancreatic cancer. Another approach is to add molecular targeting agents such as erlotinib after RICT. This may induce tumor cell death, leading to the enhanced presentation of tumor antigens to donor T cells. In addition, RICT can be combined with surgical resection, since the prognosis of pancreatic cancer is very poor even after complete resection. 19, 20 Maximum graft-versus-tumor effect can be expected when the tumor load is at its lowest level.
In conclusion, a tumor response was observed in approximately one-fourth of the patients who underwent RICT against advanced pancreatic cancer. Although the response was not durable, our findings, such as the relationship between longer survival and the infusion of a higher number of CD34-positive cells or the development of chronic GVHD, should support a future study to enhance the specific immunological effect against pancreatic cancer. Figure 2 Overall survival of patients who survived at least 100 days after transplantation grouped according to the presence or absence of chronic GVHD.
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